Tue. 26 Mar 2024, 9:28am ET
Benzinga
Earnings, News
Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.34) by 20.59 percent. This is a 35 percent decrease over losses of $(0.20) per share from the same period last year.